MX368314B - Inhibidores del mir-155 para tratar linfoma cutáneo de células t (ctcl). - Google Patents
Inhibidores del mir-155 para tratar linfoma cutáneo de células t (ctcl).Info
- Publication number
- MX368314B MX368314B MX2017015400A MX2017015400A MX368314B MX 368314 B MX368314 B MX 368314B MX 2017015400 A MX2017015400 A MX 2017015400A MX 2017015400 A MX2017015400 A MX 2017015400A MX 368314 B MX368314 B MX 368314B
- Authority
- MX
- Mexico
- Prior art keywords
- mir
- inhibitors
- cell lymphoma
- ctcl
- treating cutaneous
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3531—Hydrogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a inhibidores de oligonucleótidos del miR-155 y composiciones de los mismos. La invención proporciona además los métodos para tratar un cáncer tal como un linfoma de células T en un sujeto al administrar al sujeto un inhibidor de oligonucleótidos del miR-155. La invención también proporciona los métodos para reducir o inhibir la proliferación de células T malignas al administrar un inhibidor de oligonucleótidos del miR-155.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562171758P | 2015-06-05 | 2015-06-05 | |
PCT/US2016/035865 WO2016197024A2 (en) | 2015-06-05 | 2016-06-03 | Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl) |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2017015400A MX2017015400A (es) | 2018-06-19 |
MX368314B true MX368314B (es) | 2019-09-27 |
Family
ID=57441983
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017015400A MX368314B (es) | 2015-06-05 | 2016-06-03 | Inhibidores del mir-155 para tratar linfoma cutáneo de células t (ctcl). |
MX2019011469A MX2019011469A (es) | 2015-06-05 | 2017-11-29 | Inhibidores del mir-155 para tratar linfoma cutaneo de celulas t (ctcl). |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019011469A MX2019011469A (es) | 2015-06-05 | 2017-11-29 | Inhibidores del mir-155 para tratar linfoma cutaneo de celulas t (ctcl). |
Country Status (14)
Country | Link |
---|---|
US (5) | US9771585B2 (es) |
EP (1) | EP3303590A4 (es) |
JP (2) | JP6721252B2 (es) |
KR (2) | KR20190118688A (es) |
CN (1) | CN108138180A (es) |
AU (2) | AU2016270434B2 (es) |
BR (1) | BR112017026201A2 (es) |
CA (1) | CA2986949C (es) |
HK (1) | HK1253405A1 (es) |
IL (1) | IL255896A (es) |
MX (2) | MX368314B (es) |
NZ (1) | NZ737542A (es) |
RU (1) | RU2718534C2 (es) |
WO (1) | WO2016197024A2 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3303590A4 (en) | 2015-06-05 | 2019-01-02 | Miragen Therapeutics, Inc. | Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl) |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
WO2018009855A1 (en) * | 2016-07-07 | 2018-01-11 | MiRagen Therapeutics, Inc. | Methods for treating cutaneous t-cell lymphoma (ctcl) with mir-155 inhibitors |
EP3494228B1 (en) * | 2016-08-03 | 2021-07-07 | CBmed GmbH Center for Biomarker Research in Medicine | Method for prognosing and diagnosing tumors |
US11478500B2 (en) * | 2018-08-16 | 2022-10-25 | The Regents Of The University Of California | Anticancer compositions and methods for making and using them |
US20220054528A1 (en) * | 2018-12-03 | 2022-02-24 | MiRagen Therapeutics, Inc. | Treatment of adult t cell leukemia/lymphoma (atll) using mir-155 inhibitors |
CN112661826B (zh) * | 2020-12-25 | 2022-03-29 | 中山大学 | 小肽ERpeptide及其在急性髓系白血病中的应用 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1541463A (en) | 1975-10-11 | 1979-02-28 | Lion Dentifrice Co Ltd | Process for prparing a multiple emulsion having a dispersing form of water-phase/oil-phase/water-phase |
US4960764A (en) | 1987-03-06 | 1990-10-02 | Richardson-Vicks Inc. | Oil-in-water-in-silicone emulsion compositions |
US5260065A (en) | 1991-09-17 | 1993-11-09 | Micro Vesicular Systems, Inc. | Blended lipid vesicles |
US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
KR19980703668A (ko) | 1995-04-03 | 1998-12-05 | 콜비 안드라 엘 | 레티노이드와 리포좀을 함유하는 피부 보호용 조성물 |
US5783656A (en) | 1996-02-06 | 1998-07-21 | Japan Synthetic Rubber Co., Ltd. | Polyamic acid, polyimide and liquid crystal aligning agent |
US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
CA2294988C (en) | 1997-07-01 | 2015-11-24 | Isis Pharmaceuticals Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
UA61997C2 (en) | 1998-05-26 | 2003-12-15 | Icn Pharmaceuticals | Nucleosides with bicyclic sugar constituent, oligonucleotide and antiviral pharmaceutical composition |
US6838283B2 (en) | 1998-09-29 | 2005-01-04 | Isis Pharmaceuticals Inc. | Antisense modulation of survivin expression |
US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
EP2428569B1 (en) | 2001-09-28 | 2018-05-23 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Microrna molecules |
CA2487274A1 (en) | 2002-05-06 | 2003-11-13 | Nucleonics Inc. | Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent |
US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
JP5654722B2 (ja) | 2003-11-26 | 2015-01-14 | ユニバーシティ オブ マサチューセッツ | 短鎖rna機能の配列特異的阻害法 |
EP1713938A2 (en) | 2004-02-09 | 2006-10-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
WO2005079397A2 (en) | 2004-02-13 | 2005-09-01 | Rockefeller University | Anti-microrna oligonucleotide molecules |
EP2290074B1 (en) | 2004-05-28 | 2014-12-17 | Asuragen, Inc. | Methods and compositions involving microRNA |
AU2005272816B2 (en) | 2004-08-10 | 2011-08-11 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides |
US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
JP2008529531A (ja) | 2005-02-11 | 2008-08-07 | ウィスコンシン・アルムニ・リサーチ・ファウンデーション | Mir−155アッセイ |
WO2007016548A2 (en) | 2005-08-01 | 2007-02-08 | The Ohio State University Research Foundation | Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer |
AU2006291429B2 (en) | 2005-09-15 | 2013-04-04 | Biontech Delivery Technologies Gmbh | Improvements in or relating to amphoteric liposomes |
EP2502630B1 (en) | 2006-01-05 | 2015-03-11 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer |
EP2484782B1 (en) | 2006-01-05 | 2015-11-18 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers |
EP2591794A1 (en) | 2006-01-05 | 2013-05-15 | The Ohio State University Research Foundation | MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors |
EP1986697B1 (en) * | 2006-02-17 | 2016-06-29 | GE Healthcare Dharmacon, Inc. | Compositions and methods for inhibiting gene silencing by rna interference |
ES2446362T3 (es) | 2006-03-20 | 2014-03-07 | The Ohio State University Research Foundation | Huellas de microARN durante megacariocipoyesis humana |
NZ594605A (en) * | 2006-04-03 | 2013-03-28 | Santaris Pharma As | Pharmaceutical compositions comprising anti miRNA antisense oligonucleotides |
ES2715625T3 (es) | 2006-04-03 | 2019-06-05 | Roche Innovation Ct Copenhagen As | Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN |
MY162210A (en) | 2006-04-03 | 2017-05-31 | Roche Innovation Ct Copenhagen As | Pharmaceutical composition |
US8697672B2 (en) | 2007-05-16 | 2014-04-15 | California Institute Of Technology | Microrna inhibition for the treatment of inflammation and myeloproliferative disorders |
JP2010535473A (ja) | 2007-08-03 | 2010-11-25 | ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン | ncRNAをコードする超保存領域 |
CA2735166C (en) | 2007-08-27 | 2020-12-01 | Boston Biomedical, Inc. | Compositions of asymmetric interfering rna and uses thereof |
US7993831B2 (en) | 2007-09-14 | 2011-08-09 | Asuragen, Inc. | Methods of normalization in microRNA detection assays |
KR101889518B1 (ko) | 2007-10-04 | 2018-08-17 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 마이크로MIRs |
CN101424640B (zh) | 2007-11-02 | 2012-07-25 | 江苏命码生物科技有限公司 | 血清中微小核糖核酸的检测方法和用于检测的试剂盒、生物芯片及其制作和应用方法 |
EP2215228A4 (en) * | 2007-11-23 | 2012-01-11 | Panagene Inc | MICROARN ANTISENSE PEPTIDE NUCLEIC ACIDS (ANPs), COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING AND EVALUATING THEM |
WO2009108866A2 (en) | 2008-02-28 | 2009-09-03 | The Ohio State University Research Foundation | Microrna signatures associated with cytogenetics and prognosis in acute myeloid leukemia (aml) and uses thereof |
CA2717792A1 (en) * | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
WO2010000665A1 (en) * | 2008-06-30 | 2010-01-07 | Santaris Pharma A/S | Antidote oligomers |
EP2315832B1 (en) | 2008-08-01 | 2015-04-08 | Roche Innovation Center Copenhagen A/S | Micro-rna mediated modulation of colony stimulating factors |
RU2515926C2 (ru) * | 2009-02-04 | 2014-05-20 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Двойное нацеливание нп mir-208 и mir 499 в лечении заболеваний сердца |
CA2761106C (en) | 2009-05-05 | 2019-01-15 | Miragen Therapeutics | Lipophilic polynucleotide conjugates |
EP2459742B1 (en) | 2009-07-29 | 2016-04-06 | Pharnext | New diagnostic tools for alzheimer disease |
US20120322680A1 (en) | 2009-12-08 | 2012-12-20 | Universite Joseph Fourier | Use of mirnas as biomarkers in glioma diagnosis |
WO2011094683A2 (en) | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of identifying myelodysplastic syndromes |
US20130065946A1 (en) | 2010-03-26 | 2013-03-14 | The Ohio State University | Materials and Methods Related to Modulation of Mismatch Repair and Genomic Stability by miR-155 |
EP2553121A1 (en) | 2010-04-01 | 2013-02-06 | Department of Biotechnology | MICRORNAS (miRNA) AS BIOMARKERS FOR DETECTING DIFFERENT GRADES OF GLIOMAS AND PATHWAYS OF GLIOMA PROGRESSION |
US20120064122A1 (en) | 2010-09-13 | 2012-03-15 | David Baltimore | Treatment of autoimmune inflammation using mir-155 |
AU2011329772B2 (en) | 2010-11-17 | 2017-05-04 | Interpace Diagnostics, Llc | miRNAs as biomarkers for distinguishing benign from malignant thyroid neoplasms |
WO2012122239A1 (en) | 2011-03-07 | 2012-09-13 | The Ohio State University | MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER |
JP6021893B2 (ja) | 2011-04-18 | 2016-11-09 | ディアミール, エルエルシーDiamir, Llc | 軽度認知機能障害(MCI)およびアルツハイマー病(AD)の早期検出ならびにモニタリングのために体液からのmiRNAを使用する方法 |
EP2716758B1 (en) | 2011-06-03 | 2017-10-18 | National University Corporation Hokkaido University | OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE DERIVATIVE-CONTAINING PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PHARMACEUTICAL COMPOSITION FOR DIAGNOSIS, AND OLIGONUCLEOTIDE DERIVATIVE FOR REGULATION OF miRNA FUNCTION |
WO2013011378A1 (en) | 2011-07-15 | 2013-01-24 | Leo Pharma A/S | Diagnostic microrna profiling in cutaneous t-cell lymphoma (ctcl) |
BR112014008925A2 (pt) | 2011-10-11 | 2020-10-27 | The Brigham And Women's Hospital, Inc. | micro rnas em distúrbios de neurodegenerativos |
US9447471B2 (en) | 2011-12-29 | 2016-09-20 | Quest Diagnostics Investments Incorporated | Microrna profiling for diagnosis of dysplastic nevi and melanoma |
WO2013134403A1 (en) | 2012-03-06 | 2013-09-12 | The Washington University | Method of treating neurodegenerative diseases with microrna regulators |
US20130236453A1 (en) | 2012-03-12 | 2013-09-12 | The Ohio State University | Methods and Compositions for Modulating Acute Graft-versus-Host Disease using miR-155 Specific Inhibitors |
US20160002624A1 (en) | 2012-05-17 | 2016-01-07 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions |
CN104428005B (zh) * | 2012-05-23 | 2019-05-10 | 俄亥俄州立大学 | 用于反义寡核苷酸递送的脂质纳米颗粒组合物 |
US9603873B2 (en) | 2012-12-03 | 2017-03-28 | Ohio State Innovation Foundation | Activation of innate immunity by miRNA for cancer and infection treatment |
KR20150131365A (ko) | 2013-03-15 | 2015-11-24 | 미라젠 세러퓨틱스 인코포레이티드 | 브리지드 바이사이클릭 뉴클레오시드 |
EP3303590A4 (en) | 2015-06-05 | 2019-01-02 | Miragen Therapeutics, Inc. | Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl) |
EP3303589A4 (en) | 2015-06-05 | 2019-01-02 | Miragen Therapeutics, Inc. | Mir-155 inhibitors for treating amyotrophic lateral sclerosis (als) |
WO2018009855A1 (en) | 2016-07-07 | 2018-01-11 | MiRagen Therapeutics, Inc. | Methods for treating cutaneous t-cell lymphoma (ctcl) with mir-155 inhibitors |
-
2016
- 2016-06-03 EP EP16804580.5A patent/EP3303590A4/en not_active Withdrawn
- 2016-06-03 NZ NZ73754216A patent/NZ737542A/en not_active IP Right Cessation
- 2016-06-03 US US15/173,368 patent/US9771585B2/en not_active Expired - Fee Related
- 2016-06-03 KR KR1020197029891A patent/KR20190118688A/ko active Application Filing
- 2016-06-03 WO PCT/US2016/035865 patent/WO2016197024A2/en active Application Filing
- 2016-06-03 KR KR1020187000338A patent/KR102034619B1/ko active IP Right Grant
- 2016-06-03 JP JP2017562663A patent/JP6721252B2/ja not_active Expired - Fee Related
- 2016-06-03 BR BR112017026201-0A patent/BR112017026201A2/pt not_active Application Discontinuation
- 2016-06-03 MX MX2017015400A patent/MX368314B/es active IP Right Grant
- 2016-06-03 AU AU2016270434A patent/AU2016270434B2/en not_active Ceased
- 2016-06-03 RU RU2017146374A patent/RU2718534C2/ru active
- 2016-06-03 CA CA2986949A patent/CA2986949C/en not_active Expired - Fee Related
- 2016-06-03 CN CN201680042052.2A patent/CN108138180A/zh active Pending
-
2017
- 2017-08-15 US US15/677,818 patent/US20180127750A1/en not_active Abandoned
- 2017-09-25 US US15/714,671 patent/US9994852B2/en not_active Expired - Fee Related
- 2017-11-26 IL IL255896A patent/IL255896A/en unknown
- 2017-11-29 MX MX2019011469A patent/MX2019011469A/es unknown
-
2018
- 2018-05-10 US US15/976,333 patent/US10316318B2/en not_active Expired - Fee Related
- 2018-10-04 HK HK18112703.3A patent/HK1253405A1/zh unknown
-
2019
- 2019-04-12 US US16/382,883 patent/US20190359980A1/en not_active Abandoned
- 2019-09-20 AU AU2019232918A patent/AU2019232918A1/en not_active Abandoned
-
2020
- 2020-03-25 JP JP2020054154A patent/JP2020094073A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019011469A (es) | Inhibidores del mir-155 para tratar linfoma cutaneo de celulas t (ctcl). | |
CR20190478A (es) | Inhibidores de pd-1/pd-l1 | |
MX2023005804A (es) | Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7). | |
EP4265261A3 (en) | Methods and compositions for inhibiting expression of ldha | |
MX2022005216A (es) | Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7). | |
MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
IN2014DN09134A (es) | ||
PH12018500869A1 (en) | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment | |
IN2014CN02501A (es) | ||
MX360404B (es) | Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr. | |
PH12014502588A1 (en) | Catechol o-methyltransferase activity inhibiting compounds | |
MX367389B (es) | Compuestos y sus metodos de empleo. | |
EP4252851A3 (en) | Ezh2 inhibitors for treating lymphoma | |
MX2013008212A (es) | Derivados de 7-azaindol. | |
PH12014501032A1 (en) | 2-thiopyrimidinones | |
WO2019023315A3 (en) | RAC INHIBITORS | |
GEP201706687B (en) | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | |
TN2014000086A1 (en) | Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors | |
MX2017011018A (es) | Inhibicion de la actividad de olig2. | |
MX2016009655A (es) | Metodos novedosos para el tratamiento del cancer. | |
EP2576536A4 (en) | INHIBITORS OF HEMATOPOIETIC PROSTAGLANDIN D2 SYNTHASE | |
WO2018193476A3 (en) | ANTICANCER COMPOUNDS | |
MX2018004977A (es) | Inhibidores heterociclicos de la proteina cinasa 1 dependiente de 3-fosfoinositido (pdk1) para usarse en el tratamiento del cancer. | |
MX2015014036A (es) | Inhibidores de metastasis. | |
MX2020005251A (es) | Composiciones para mejorar la funcionalidad de células car-t y uso de las mismas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |